Item 7.01. Regulation FD Disclosure.
In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the investor presentation and abstract attached to this report as Exhibits 99.1 and 99.2, respectively, are "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.
Any statements contained in the investor presentation and abstract that do not
describe historical facts may constitute forward-looking statements. These
forward-looking statements include statements regarding the Company's plans to
explore strategic alternatives and the potential outcome and benefits of a
potential strategic transaction, the Phase 2 study and further studies, and
continued development of use of Bryostatin-1 for Alzheimer's disease and other
cognitive diseases. Such forward-looking statements are subject to risks and
uncertainties and other influences, many of which the Company has no control
over. There can be no assurance that the Company will be able to identify
potential strategic transactions and complete any transactions it may pursue or
realize the expected benefits from a strategic review or a strategic
transaction, the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy, that the Company will not encounter
problems or delays in clinical development, or that Bryostatin-1 will ever
receive regulatory approval or be successfully commercialized. Actual results
and the timing of certain events and circumstances may differ materially from
those described by the forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause actual results to
differ materially from expected or desired results may include, without
limitation, the Company's inability to identify potential strategic transactions
and to complete any transactions it pursues, the Company's inability to obtain
adequate financing, the significant length of time associated with drug
development and related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand its business,
significant government regulation of pharmaceuticals and the healthcare
industry, lack of product diversification, availability of the Company's raw
materials, existing or increased competition, stock volatility and illiquidity,
and the Company's failure to implement its business plans or strategies. These
and other factors are identified and described in more detail in the Company's
filings with the
Item 9.01 Financial Statements and Exhibits
(d) Exhibits. 99.1 Investor Presentation, datedFebruary 26, 2020 . 99.2 Abstract, datedFebruary 26, 2020 .
© Edgar Online, source